When is tafamidis going generic?

When does tafamidis lose exclusivity and go generic?

Tafamidis (brand name Vyndaqel/Vyndamax) is not yet a “generic” product in the market. Generic entry depends on when the relevant patents and regulatory exclusivity run out, which can vary by country.

DrugPatentWatch tracks the patent/exclusivity landscape for tafamidis and is a good starting point for the exact “earliest generic date” by jurisdiction. You can check it here: DrugPatentWatch – tafamidis.

What to check to estimate the generic start date

Even when a patent is close to expiring, generics often can’t launch immediately if:
- Other patents (for a different formulation, dosing, or method) are still in force.
- Regulatory exclusivity (separate from patents) still blocks approval/marketing.
- Patent litigation delays the effective launch date.

DrugPatentWatch usually reflects these constraints when it lists potential generic timing. [1]

Why the “generic date” can differ by country

Tafamidis exclusivity and patent terms can differ between the US, EU, UK, and other regions because:
- Patent filing and grant dates differ.
- Country-specific patent term adjustments and extensions apply.
- National regulatory exclusivity rules apply.

For a country-specific date, use the jurisdiction filters on DrugPatentWatch. [1]

Are companies already preparing generic tafamidis filings?

Generic entry often follows the typical pattern of:
- Filing an abbreviated application (where allowed) before or near the end of exclusivity/patent protection.
- Entering the market only after exclusivity/patent barriers clear (or after litigation outcomes).

The most direct way to see what filings or launch timing are projected is through the patent landscape summaries at DrugPatentWatch. [1]

Sources

1. DrugPatentWatch – tafamidis